A step-wise approach was adopted to narrow down the number of options. The evaluation was conducted with support from an external financial advisor with the aim to maximize shareholder value. The Board has decided to proceed with the recommended reverse merger. Further steps are now being taken to ensure that the potential transaction is achievable. The Company expects to be able to provide more details before the annual general meeting on
The decision on how to proceed will be subject to shareholder approval at a later extraordinary general meeting.
For more information:
Phone: +46 8 122 038 50
E-mail: jenny.sundqvist@indexpharma.com
Johan Giléus, CFO and deputy CEO
Phone: +46 8 122 038 50
E-mail: johan.gileus@indexpharma.com
Publication
The information was submitted for publication through the agency of the contact person set out above at 14.20 CET on
This is an English translation of the Swedish press release. In case of discrepancies between the English translation and the Swedish press release, the Swedish press release shall prevail. Information in this press release is intended for investors.
https://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-provides-a-company-update,c3958034
https://mb.cision.com/Main/9612/3958034/2716983.pdf
(c) 2024 Cision. All rights reserved., source